Intas to provide 2 million hydroxychloroquine tablets for WHO study on COVID-19

Intas informed that it is collaborating on the WHO-endorsed study
using hydroxychloroquine, a drug that may have an effect in preventing
and/or reducing symptoms of COVID-19. The global COPCOV (chloroquine /
hydroxychloroquine prevention of COVID-19 in the healthcare setting; a
randomised, placebo-controlled prophylaxis).

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/intas-to-provide-2-million-hydroxychloroquine-tablets-for-who-study-on-covid-19/articleshow/74891846.cms